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Mutations in LOXHD1, a Recessive-Deafness Locus,
Cause Dominant Late-Onset Fuchs Corneal Dystrophy
S. Amer Riazuddin,1 David S. Parker,2 Elyse J. McGlumphy,1 Edwin C. Oh,2 Benjamin W. Iliff,1
Thore Schmedt,3 Ula Jurkunas,3 Robert Schleif,4 Nicholas Katsanis,2 and John D. Gottsch1,*
Fuchs corneal dystrophy (FCD) is a genetic disorder of the corneal endothelium and is the most common cause of corneal transplanta-
tion in the United States. Previously, we mapped a late-onset FCD locus, FCD2, on chromosome 18q. Here, we present next-generation
sequencing of all coding exons in the FCD2 critical interval in a multigenerational pedigree in which FCD segregates as an autosomal-
dominant trait. We identified a missense change in LOXHD1, a gene causing progressive hearing loss in humans, as the sole variant
capable of explaining the phenotype in this pedigree. We observed LOXHD1 mRNA in cultured human corneal endothelial cells,
whereas antibody staining of both human and mouse corneas showed staining in the corneal epithelium and endothelium. Corneal
sections of the original proband were stained for LOXHD1 and demonstrated a distinct increase in antibody punctate staining in the
endothelium and Descemet membrane; punctate staining was absent from both normal corneas and FCD corneas negative for causal
LOXHD1 mutations. Subsequent interrogation of a cohort of >200 sporadic affected individuals identified another 15 heterozygous
missense mutations that were absent from >800 control chromosomes. Furthermore, in silico analyses predicted that these mutations
reside on the surface of the protein and are likely to affect the protein’s interface and protein-protein interactions. Finally, expression of
the familial LOXHD1mutant allele as well as two sporadic mutations in cells revealed prominent cytoplasmic aggregates reminiscent of
the corneal phenotype. All together, our data implicate rare alleles in LOXHD1 in the pathogenesis of FCD and highlight how different
mutations in the same locus can potentially produce diverse phenotypes.Fuchs corneal dystrophy (FCD) is the most common
genetic disorder of the corneal endothelium1–3 and
accounts for a significant portion of corneal transplanta-
tion performed in the United States every year.4,5
Clinically, FCD is marked by the development of guttae,
excrescences of the Descemet membrane that typically
appear in the fourth or fifth decade of life and increase in
number over time.6,7 As the disease progresses, visual
acuity decreases secondary to corneal edema and endothe-
lial cell loss, and the last stage of the disease is evidenced by
painful epithelial bullae.8
FCD is genetically heterogeneous. A rare early-onset
form of an endothelial dystrophy with some of the clinical
features of FCD has been ascribed to mutations in COL8A2
(MIM 12052),9,10 whereas rare mutations in SLC4A11
(MIM 610206) and TCF8 (MIM 189909) have been impli-
cated in the pathogenesis of the common form of late-
onset FCD.9–14 Additionally, large pedigrees that exhibit
dominant inheritance have been used for mapping four
loci—FCD1, FCD2, FCD3, and FCD4—on chromosomes
13, 18, 5, and 9, respectively.13,15–17 Finally, rs613872, an
intronic SNP at the TCF4 (MIM 602272) locus on chromo-
some 18q, has also been associated with late-onset
FCD.18–20 However, haplotype analyses have suggested
that this risk factor is probably independent of FCD2,19
intimating that multiple loci might account for the linkage
and association signals on 18q.
Previously, we reported on three large families with
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The AmeLOD scores >3 on 18q. To identify mutations that cause
the disorder in these pedigrees, we generated a custom
exon-capture library that includes all annotated exons in
the most conservative critical region, which is defined as
aminimumof two recombination events at each boundary
and spans 26 Mb. Given the complexity of the phenotype
and the documented presence of both nonpenetrance and
phenocopies, we extended our capture target region by 5
MB on each side.
One affected and one unaffected individual per family
were sequenced at the Genetic Variation and Gene
Discovery Core Facility at Cincinnati Children’s Hospital.
Exon capture with a Roche/Nimblegen 385k chip and
next-generation paired-end sequencing on an Illumina
GAIIx instrument generated on average 1.5 GB of data per
sample; these data correspond to approximately 25million
36 bp reads. We captured 98% of the target with an average
read depth of 953, and only a small fraction (0.01%) of
the sequences had coverage less than 253. The raw data
were aligned to the reference sequence by Eland (Illumina),
and alleles were called by Seqmate software.
We analyzed the coding sequence and intron-exon junc-
tions of 134 genes. For two of the three families, we found
no changes that could explain the disorder. This was
true not only for rare alleles (minor allele frequency
[MAF] <1%), which would have been the expectation
from linkage analysis (LOD scores were calculated with a
disease allele frequency of 0.01), but also for more
common alleles. In addition, we could not observe anyore, MD 21287, USA; 2Center for HumanDiseaseModeling, Department of
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Figure 1. Cyrillic Pedigree of Family HU with the c.1639C>T (p.Arg547Cys) Mutation Segregating with the Disease Phenotype in the
Family
The filled symbols represent affected individuals. A diagonal line through a symbol represents a deceased individual. A question mark
indicates that the affectation status of an individual is unknown. Haplotypes of 18q microsatellite markers are shown, and the alleles
forming the disease-bearing haplotype are shaded black.overtransmission of common alleles because our study
design could not detect association. As such, the causal
mutations in these two families could be common, in
which case theymight act in conjunction with trans alleles
at other loci, as shown for FCD4,13 could reside in regions
that were not captured (such regions are either the 2% that
failed capture or the regulatory elements that were not tar-
geted), or could represent larger CNVs that were undetect-
able by our tools.
For the third family (HU: Kindred II in Sundin et al.),
however, we identified a C>T transition, c.1639C>T
(p.Arg547Cys), in LOXHD1 (MIM 613072; RefSeq acces-
sion number NM_144612.6), and it was predicted by Poly-
Phen2 to be probably pathogenic. The variant was absent
from both the 1,000 Genomes Project and the 1,500
sequenced exomes available from the University of Seattle
Exome Variant Server. Moreover, the allele was unique to
the affected individuals of family HU with the exception
of one individual (individual III:1; Figure 1). Our clinical
records showed that deceased individual II:2 was never
examined, and we therefore cannot rule out the possibility534 The American Journal of Human Genetics 90, 533–539, March 9that this individual was affected and subsequently trans-
mitted the causal mutation to his offspring (affected indi-
viduals III:1 and III:2). We also did not detect this change
in 384 chromosomes of individuals who were older than
60 years of age and whose corneas were phenotypically
normal (no guttae) upon slit-lamp examination; this
finding is consistent with the allele being pathogenic.
Recently, this variation was identified in one individual
(Bushman: rs113444922) of African descent in a whole-
genome sequencing project; however, the variation was
never validated, and,more importantly, there isno informa-
tion available regarding the phenotype of this individual.
The sequencing results were of high quality, and there is
no reason to expect that we had missed the allele associ-
ated with FCD. Nevertheless, to bolster confidence in our
findings, we sequenced the entire exome of the proband
(individual II:5) by using Agilent whole-human-exome
liquid capture array and sequenced the captured regions
on Illumina HighSeq2000. The raw data were aligned to
the reference sequence by ELAND, and our results recon-
firmed our previous findings. All together, the results, 2012
Figure 2. Immunohistochemical Analyses of LOXHD1 in 20 mm
Cryosections of Mouse Cornea
(A and B) A slide stainedwith the LOXHD1 antibody (A) and a slide
stained with both DAPI and the LOXHD1 antibody (B). LOXHD1
is present both in the corneal epithelium and in the endothelium;
however, the level of LOXHD1 is much higher in the epithelium
than in the endothelium.
(C and D) A slide stained with a LOXHD1 antibody þ503 peptide
(C) and a slide stained with both DAPI and a LOXHD1 antibody
þ503 peptide (D). The expression in the corneal epithelium and
endothelium could be competed away with a commercially avail-
able LOXHD1 peptide.
The arrows point to the LOXHD1 present in the corneal
endothelium.from both the target capture and the exome sequencing
strongly advocate for the candidacy of LOXHD1.
As a first step toward assessing the candidacy of
LOXHD1, we examined the expression of this transcript
in the cornea. Previously, Grillet and colleagues reported
the expression of Loxhd1mRNA in cochlear and vestibular
hair cells in P4 mice.21 First, we asked whether LOXHD1
expression was present in cultured human corneal endo-
thelial cells. These were grown in cultured FBS medium.
Upon confluence, the cells were harvested, and total RNA
was extracted with Trizol (Invitrogen, CA). cDNA was
synthesized with a commercially available kit (Invitrogen,
CA) with polydT and LOXHD1 specific primers. We per-
formed quantitative RT-PCR in triplicate on Applied Bio-
systems 7900HT by using gene-specific Taqman probes
(Applied Biosystems, CA). We analyzed the results with
the sequence-detection software (Applied Biosystems,
CA). For each group, we calculated the mean cycle
threshold (CT) value for each target (LOXHD1) and endog-
enous reference (GAPDH and b-actin); these CT values
represent the PCR cycle at which the ABI 7900 HT Detec-
tion System first detects a noticeable increase in reporter
florescence above the baseline signal. We observed ex-The Amepression of LOXHD1 in cultured human corneal endothe-
lial cells at levels 5 orders of magnitude lower than
that of GAPDH (MIM 138400) or b-actin (MIM 102630)
(Table S1, available online).
We next examined the presence of LOXHD1 in mouse
corneas. P120 (postnatal day 120) mouse eyes were enucle-
ated and flash frozen in optimal cutting medium. Blocks
were cryosectioned and 20 mm sections on slides were fixed
with 4% paraformaldehyde in a phosphate buffer for
10 min. The corneal distribution of LOXHD1 was visual-
ized with a rabbit polyclonal LOXHD1 antibody (Santa
Cruz Biotechnology, SC85038) at a 1:400 dilution over-
night at 4C, and treatment with goat anti-rabbit IgG
conjugated with AlexaFluor 594 (Invitrogen, A11012) at
a 1:1000 dilution for 1 hr at 25C followed. Nuclei were
counter stained with DAPI (at a 1:20000 dilution), and
images were captured with a Zeiss LSM 710 Meta and digi-
talized with Zen software. We detected LOXHD1 both in
the corneal epithelium and in the endothelium; however,
expression was significantly higher in epithelial cells
(Figures 2A and 2B). Importantly, LOXHD1 expression in
the corneal epithelium and endothelium could be
competed away with a LOXHD1 peptide (Santa Cruz
Biotechnology, SC85038P), suggesting that the antibody
is specific to LOXHD1 (Figures 2C and 2D).
We next asked whether we could observe LOXHD1
defects at the site of the pathology in the cornea of the
proband. We were able to examine the distribution of
LOXHD1 in the cornea, which was obtained at the time
of corneal transplantation, of individual II:5 (indicated
by an arrow in Figure 1). One control cornea was from
a transplanted FCD patient who had been screened and
found not to have any coding nonsynonymous variants
in LOXHD1. Another control cornea was non-Fuchs tissue
obtained from an individual who had been transplanted
for keratoconus and who had normal corneal endothe-
lium. Tissue was fixed with formaldehyde and embedded
in paraffin. The 10 mm-thick sections were treated with
rabbit polyclonal LOXHD1 antibody at a 1:250 dilution
for 4 hr at room temperature or overnight at 4C, and treat-
ment with goat anti-rabbit IgG conjugated with AlexaFluor
594 (Invitrogen) followed. Slides were costained for nuclei
with DAPI (in a 1:5000 dilution). Sectioned images were
captured with a Zeiss LSM 710 Meta and were digitalized
with Zen software.
Examination of corneal sections in which the genotype
was masked showed a distinct increase in staining in the
corneal endothelium and Descemet membrane of the
proband with the c.1639C>T (p.Arg547Cys) LOXHD1
mutation (Figures 3A, 3D, and 3G)when compared to the
non-LOXHD1 Fuchs (Figures 3B, 3E, and 3H) and keratoco-
nus controls (Figures 3C, 3F, and 3I). Furthermore, we
observed multiple aggregate staining in the corneal endo-
thelium of HU-II-5 and a clearly distinguishable increase
in protein abundance in the Descemet membrane, as
well as increased thickness of the membrane—a pathogno-
monic hallmark of FCD. Together with our mutationalrican Journal of Human Genetics 90, 533–539, March 9, 2012 535
Figure 3. Immunohistochemical Analyses of LOXHD1 in Human Corneal Endothelium and Descemet Membrane
(A) Fuchs-affected individual harboring the c.1639C>T (p.Arg547Cys) LOXHD1 mutation.
(B) Fuchs-affected individual negative for any causal LOXHD1 mutation.
(C) Keratoconus-affected individual negative for Fuchs corneal dystrophy (note: panels D, E, F, G, H, and I are enlarged images of
the boxed areas in panels A, B, and C). Aggregates of LOXHD1 are noted in the corneal endothelium and throughout the thickened
Descemetmembrane of a Fuchs patient harboring the c.1639C>T (p.Arg547Cys) LOXHD1mutation. Few protein deposits in the corneal
endothelium (‘‘CE’’) and Descemet membrane (‘‘DM’’) are seen in a Fuchs patient negative for any causal LOXHD1mutation and in the
patient transplanted for keratoconus. Note: The gain (exposure) is an order of magnitude higher in (C) than in (A) and (B).data, these studies indicate that the LOXHD1mutation has
a causal role, most likely through a mechanism of protein
aggregation in the endothelium and Descemet membrane,
in the HU family.
To further investigate the contribution of LOXHD1 to
the total genetic load of late-onset FCD, we interrogated
our entire cohort of small nuclear families and sporadic
cases. Recruitment, examination, and procedures for
DNA-sample collection were approved by the institutional
review boards for human subjects research at the Johns
Hopkins University School of Medicine and were in accor-
dance with the Declaration of Helsinki. All participating
individuals gave informed written consent and underwent
detailed ophthalmic examination, including slit-lamp
biomicroscopy. Severity was graded on a modified scale
according to Krachmer and colleagues; >12 central guttae
in one eye was indicative of disease (grade 1) in individuals
over 40 years of age.6
We sequenced all coding exons of LOXHD1with Big Dye
Terminator Ready Reaction Mix according to the manufac-
turer’s (Applied Biosystems) instructions as described.13, 14
Primer pairs are available upon request. We identified 14
additional nonsynonymous coding variants (one variant,
c.5272A>T [p.Thr1758Ser], was found in two sporadic
affected individuals) and a missense variant, c.1904T>C
(p.Leu635Pro), in the LOXHD1 splice isoform (RefSeq
accession number NM_001145472) in our cohort of 207
unrelated subjects (Figure 4A and Table S2A). None of these536 The American Journal of Human Genetics 90, 533–539, March 9alleles were present in 384 ethnically matched control
chromosomes, and they were also not reported in the
1,000 Genome Project or the 1,500 exome project. Addi-
tionally, we found the mutated residues to be highly
conserved in other LOXHD1 orthologs, and, with the
exception of one variant, c.1945G>A (p.Asp649Asn), all
are predicted to be damaging (Table S2A).
Despite this apparent enrichment of pathogenic alleles,
sequencing data from the 1,000 Genomes Project and Seat-
tle exomes suggested that multiple LOXHD1 variants that
are absent from dbSNP are present in the general popula-
tion; this suggestion raises the possibility that the alleles
discovered in our sporadic cases represent chance events.
To investigate this possibility, we sequenced all coding
exons of LOXHD1 in 288 unaffected and unrelated control
samples (576 chromosomes); we identified eight variants
that were not present in any database. Nevertheless, the
variants were predicted to be pathogenic by PolyPhen2
algorithms (Figure 4A and Table S2B). Furthermore, the
1,500 exome project had previously identified in 550
samples of European descent 12 variants that were pre-
dicted to be damaging by PolyPhen2. We therefore asked
whether there were more damaging alleles in our cases
than in our controls. Analysis of these data showed a signif-
icant enrichment (p ¼ 0.003), which, together with the
absence of these damaging alleles from ~2,000 control
chromosomes, suggests that the observed mutational
load of this locus is relevant to FCD., 2012
Figure 4. LOXHD1 Variants Identified in Late-Onset FCD Cases and Phenotypically Normal Control Samples
(A) Schematic representation of LOXHD1 variations identified in FCD cases (red) and phenotypically normal controls (purple). Also
shown is the localization profile of the variations identified in FCD cases (B) and normal controls (C) in the homology model that
was constructed with the crystal coordinates of human lipoxygenase. This model suggests that most of these residues that mutated
in late-onset FCD lie on the surface of the protein. In addition to 15 variations, a missense variant, c.1904T>C (p.Leu635Pro), was iden-
tified in the LOXHD1 splice isoform (NM_001145472), and it was not present in 384 ethnically matched control chromosomes.Cognizant of the imperfect predictive nature of Poly-
Phen and the relatively modest number of FCD cases
sequenced, both of which could lead to false-positive
results, we asked whether the three-dimensional structure
of LOXHD1 displays nonrandom distribution of the
private variants found in our cases. We therefore con-
structed a three-dimensional structure of LOXHD1 by
using the coordinates of human lipoxygenase (Figures 4B
and 4C). The degree of amino acid identity ranged between
26% and 39%, which is sufficient to ensure tertiary-struc-
ture alignment with human lipoxygenase.22 The model
predicts that most of the mutations identified in our cases
reside on the surface of the protein, making them more
likely to affect the way in which the protein interacts
with other proteins. This homologymodel further suggests
that conservatively, 5 out of the 15 variants identified in
our cohort, including the allele identified in family HU,
reside in the interdomain linker regions. In contrast,
most of the variants (seven out of eight) identified in our
phenotypically normal controls are present in structured
regions. These data predict that substituting amino acidsThe Amethat have aromatic or cyclic side chains for positively
charged amino acids is bound to increase hydrophobicity
of these linker regions and result in conformational
changes, whereas the arginine to cysteine changes poten-
tially allow for disulfide formation.
The structural model of the protein predictions is consis-
tent with the detection of apparent aggregates in the
cornea of the individual from family HU. To probe this
possibility further, we expressed the HU mutation and
two other randomly chosen alleles in ARPE-19, a cell line
derived from the human retinal pigment epithelium, and
we used expression of wild-type LOXHD1 as a negative
control. We grew ARPE-19 cells in Dulbecco’s Modified
Eagle Medium and Ham’s F-12 Nutrient 1:1 mixture
(DMEM/F-12, Invitrogen) with 10% FBS and 2mML-gluta-
mine. We used FuGene6 Transfection Reagent (Roche) to
transfect the cells with plasmids harboring the wild-type
Loxhd1 tagged at the N-terminus with GFP, plasmids
harboring the HU mutation, or plasmids harboring two
other alleles randomly picked from our cohort. Strikingly,
analysis of ~100 transfected cells masked to therican Journal of Human Genetics 90, 533–539, March 9, 2012 537
Figure 5. Localization of GFP-Tagged Wild-Type and Mutant LOXHD1
ARPE-19 cells were transfected with plasmids harboring (A) wild-type, (B) c.469C>T (p.Arg157Cys), (C) c.1639C>T (p.Arg547Cys), and
(D) c.2251C>T (p.Arg751Trp) Loxhd1 tagged at the N-terminus with GFP. The wild-type LOXHD1 is present throughout the cytoplasm,
whereas the p.Arg157Cys, p.Arg547Cys, and p.Arg751Trp mutant proteins show puncta in transfected cells.transfection cocktail showed distinct cytoplasmic puncta
in cells expressing each of the three mutants; cytoplasmic
puncta were seen rarely in cells expressing the wild-type
protein (Figure 5). Althoughwe are cautious in interpreting
data gathered from a heterologous in vitro system, these
observations are consistent with both the endogenous
findings in the affected cornea and our three-dimensional
protein model.
LOXHD1 is an evolutionarily conserved protein pre-
dicted to consist of 15 PLAT (polycystin-1, lipoxygenase,
alpha-toxin) domains. The biological function of PLAT
domains is not well established, but it is posited that
they target proteins to the plasma membrane.21 Although
the exact mechanism of late-onset-FCD causality associ-
ated with LOXHD1 mutations identified in our cohort is
not yet clear, the presence of marked precipitates in the
corneas of our index family suggests that some fraction
of FCD might be caused by aggregation defects similar to
other late-onset degenerative disorders, such as limb-girdle
muscular dystrophy and Parkinson disease.23,24 In that
context, determining the composition of these aggregates
might reveal important clues regarding pathomechanism.
Furthermore, LOXHD1 appears to be expressed at low
abundance in the cornea, whereas our results suggest
that high levels of protein in cells induced aggregate
formation, exacerbated further by the presence of muta-
tions. These results raise the possibility that increased
LOXHD1 concentrations might have long-term cytotoxic
effects. Therefore, we speculate that transcriptional upre-
gulation independent of coding-sequence mutations
might also predispose individuals to late-onset FCD.
Finally, LOXHD1 is the second FCD locus involved in
both corneal dystrophy and deafness; SLC4A11, a
sodium-borate transporter, has been associated with both
congenital hereditary endothelial dystrophy with progres-
sive deafness (Harboyan syndrome: MIM 217400) and
late-onset FCD.12,14,25 To date, two causal mutations,
c.2008C>T (p.Arg670*) and c.4714C>T (p.Arg1572*), in
LOXHD1 have been associated with hearing loss.21,26
Many of the affected individuals in our Fuchs cohort
harboring rare LOXHD1 variants did self report hearing538 The American Journal of Human Genetics 90, 533–539, March 9impairment, and recently, hearing disability was reported
in FCD cases, suggesting an association between FCD and
hearing disability.27 Nonetheless, we are cautious when
inferring causal links from these observations, given that
(1) FCD is a disorder typically diagnosed in people in their
5th or 6th decade of life (or older), and assessing comorbid-
ities between two common traits is challenging, and (2)
although we have observed significantly more coding
LOXHD1 changes in our cases than in our controls, inter-
preting with confidence the causal potential of any single
allele within that series is not possible. Exploring the
possible links between common hearing deficits and FCD
will require significant replication of our studies.Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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